TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Last earnings +11.9% on 2026-04-29
$34.64
▲ +3.99%$34.64▲ +106.68%
over 1Y
L $15.38H $36.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.0%
1W+3.0%
1M+4.7%
3M+15.2%
YTD+11.9%
1Y+106.7%
Hold
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 7 analysts
Buy
Teva's turnaround is real — back to profit, growing, deleveraging — but a 26x P/E and a leveraged, generics-heavy base cap the upside.
Net income $1.41B · FY2025
The read
Middling fundamentals offset by an attractive price (~30% below fair value) — worth a look on the value angle.
FY2025 is a genuine inflection. After three straight years of GAAP losses (-$2.45B in 2022, -$559M in 2023, -$1.64B in 2024), Teva delivered $1.41B net income (+186%) on $17.3B revenue (+4.3%). Operating income leapt to $2.16B (+812%), diluted EPS to $1.21 (+183%), and operating cash flow to $1.65B (+32%) — funding roughly $1.15B of free cash after $501M capex. Stockholders' equity rebuilt +47% to $7.91B, and ROE printed 17.8% on a 51.8% gross margin. The 10-K's 'Pivot to Growth' strategy is showing up in the numbers, not just the narrative.
The balance sheet is improved but still the binding constraint. The MD&A shows total debt of $16,807M, now entirely fixed-rate with a laddered maturity profile ($1.82B due 2026, $5.52B in 2031 and beyond). Against $3.56B cash that is ~$13.2B net debt — materially reduced and manageable, but liabilities/equity sits at 4.15x and retained earnings are -$13.8B, the scar tissue of past impairments and opioid/price-fixing litigation. Equity is thin enough that a fresh charge would bite hard.
Is TEVA a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~34.64
- Short call 36 @ ~1.62 est
debit $3,302max +$298max −$3,301BE 33.02
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Gross profit | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| Operating income | $1.72B | -$2.20B | $433M | -$303M | $2.16B |
| Net income | $417M | -$2.45B | -$559M | -$1.64B | $1.41B |
| Diluted EPS | $0.38 | -$2.20 | -$0.50 | -$1.45 | $1.21 |
| Net margin | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$67.4B
EV / EBITDA21.3
EV / Sales3.9
EV / FCF58.7
P / FCF35.1
PEG (trailing)0.15
Earnings yield3.5%
FCF yield2.8%
Quality & risk
ROIC (est.)4.4%
Free cash flow$1.15B
Total debt$30.6B
Net cash-$27.1B
Altman Z-Score0.88 distress
Piotroski F-Score8/9
Capital returns
Buyback yield1.2%
Dividend yield (est.)0.0%
Shareholder yield1.3%
Shares Δ YoY+1.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-05-28
AGM vote results: board elected and routine proposals approved
- 8-K Earnings results2026-04-29
Q1 2026 10-Q: revenue growth and profitability sustained
- 10-Q Quarterly report2026-04-29
Q1 2026 10-Q: revenue growth and profitability sustained
- DEF 14A Proxy statement2026-03-31
2026 proxy: board slate, exec comp and auditor up for vote
- 10-K Annual report2026-02-03
FY2025 10-K: returned to profit; operating income +812%, equity +47%
- 8-K Earnings results2026-01-28
Q4/FY2025 results: returned to profit, net income $1.41B (+186%)
- 8-K Earnings results2026-01-12
Preliminary FY2025 results and 2026 outlook (JPM conference)
- 8-K Material agreement2025-12-11
New senior-notes/debt agreement to refinance and extend maturities
- 8-K Earnings results2025-11-05
Q3 2025 10-Q: revenue up, narrowing toward full-year profit
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-22open ↗144Filing2026-06-18open ↗4Period ending 2026-06-112026-06-16open ↗144Filing2026-06-11open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗
Frequently asked
- Is TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) a buy?
- TEVA currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Teva's turnaround is real — back to profit, growing, deleveraging — but a 26x P/E and a leveraged, generics-heavy base cap the upside.
- What is TEVA's fair value?
- A Modified-Graham model based on TEVA's SEC fundamentals estimates a fair value of about $45.19. It is an estimate from reported earnings, not a price target.
- Is TEVA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, TEVA currently appears undervalued relative to its SEC-grounded earnings power.
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's quality score?
- TEVA scores 72.38063043939918/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000818686, latest 10-Q filed 2026-04-29) · EODHD · Proprietary analysis · as of 6/20/2026, 12:18:55 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 8:18 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.